ğŸ§¬ GENE OF THE WEEK: PCSK9

Some people are born with LDL so low they're nearly immune to heart disease. They have loss-of-function PCSK9 mutations. Now we can mimic this with drugs.

PCSK9 controls how many LDL receptors are on liver cells. More receptors = more LDL cleared from blood = lower LDL levels.

How PCSK9 Controls Your LDL:

1ï¸âƒ£ LDL receptor grabs LDL from blood
2ï¸âƒ£ PCSK9 tags the receptor for destruction
3ï¸âƒ£ Fewer receptors = higher LDL

If you block PCSK9, receptors survive longer, and LDL drops dramatically.

The Genetic Variants:

âœ“ Loss-of-Function (Protective)
3% of African Americans carry these variants. Their LDL is 30-40% lower lifelong. They have 88% lower heart disease risk. No apparent health downsides.

ğŸš¨ Gain-of-Function (Harmful)
Causes familial hypercholesterolemia. Very high LDL from birth. Heart attacks in 30s-40s without treatment.

PCSK9 Inhibitor Drugs:

ğŸ’‰ Evolocumab (Repatha)
ğŸ’‰ Alirocumab (Praluent)
Injectable antibodies that block PCSK9. Lower LDL by 50-60% on top of statins. Given every 2-4 weeks.

ğŸ’‰ Inclisiran
siRNA that silences PCSK9 gene. Only needs to be given twice per year. Recently approved.

Who Benefits Most:

â†’ Statin-intolerant patients
â†’ Familial hypercholesterolemia
â†’ Very high cardiovascular risk despite statins
â†’ Recurrent events on max therapy

The lesson: Genetic "experiments of nature" showed us PCSK9 inhibition is safe and profoundly protective. Then we made drugs to mimic it.

ğŸ‘¨â€âš•ï¸ Physicians: Why aren't you using Bioscope.AI to offer true AI-powered precision medicine?

ğŸ§‘ Patients: Why isn't your physician using Bioscope.AI to maximize your healthy longevity?

#GeneOfTheWeek #PCSK9 #Cholesterol #CardiovascularHealth #PrecisionMedicine #Bioscope
